Machida, Japan

Akiko Shimizu




Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 14(Granted Patents)


Company Filing History:


Years Active: 2010-2020

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Akiko Shimizu: Innovator in Antibody Development

Introduction

Akiko Shimizu is a prominent inventor based in Machida, Japan. She has made significant contributions to the field of biotechnology, particularly in the development of human CDR-grafted antibodies. With a total of 6 patents to her name, her work has the potential to impact therapeutic and diagnostic applications.

Latest Patents

Among her latest patents is a human CDR-grafted antibody and antibody fragment that specifically reacts with the extracellular region of the human CC chemokine receptor 4 (CCR4). This invention is notable for its specificity, as it does not react with human blood platelets. Additionally, her work includes a human CDR-grafted antibody that exhibits cytotoxic activity against CCR4-expressing cells. These antibodies can be utilized in the development of medicaments, therapeutic agents, or diagnostic agents, making them valuable in medical research and treatment.

Career Highlights

Akiko Shimizu has worked with notable companies in the biotechnology sector, including Kyowa Hakko Kirin Co., Limited and Kyowa Kirin Co., Ltd. Her experience in these organizations has allowed her to refine her expertise in antibody development and contribute to innovative solutions in healthcare.

Collaborations

Throughout her career, Akiko has collaborated with esteemed colleagues such as Kenya Shitara and Kazuyasu Nakamura. These partnerships have fostered a collaborative environment that enhances the research and development of new biotechnological advancements.

Conclusion

Akiko Shimizu's contributions to the field of biotechnology, particularly in the development of human CDR-grafted antibodies, highlight her innovative spirit and dedication to advancing medical science. Her work continues to pave the way for new therapeutic and diagnostic possibilities.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…